Interferon-beta: Clinical Trials

7 trials of Interferon-beta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated, 1 recruiting. 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 37Completed 4, Terminated 2, Recruiting 1

Follow Interferon-beta: new trials by email Literature Review of Interferon-beta trials Research Report on Interferon-beta

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
Phase 3RecruitingUniversity Hospital, Montpellier2502026-06-152026-06-23
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
Colchicine, Interferon-Beta, Aspirin - Coronavirus, Severe Acute Respiratory Syndrome
Phase 3CompletedPopulation Health Research Institute66672020-04-212024-01-11
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon - Multiple Sclerosis
Phase 3TerminatedGenzyme, a Sanofi Company162017-10-232026-08-04
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
MP-424, RBV(24 weeks), IFN beta(24 weeks) - Chronic Hepatitis C(CHC)
Phase 3CompletedTanabe Pharma Corporation742012-12-012026-01-06
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta) - Multiple Sclerosis Relapse
Phase 3TerminatedSanofi5342011-01-012014-06-09
Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis
Interferon beta, Methotrexate - Uveitis, Intermediate, Macular Edema
Phase 3CompletedHeidelberg University192006-03-012012-12-03
Optimizing IFN Beta - 1B Dose
Interferon Beta 1 - Multiple Sclerosis
Phase 3CompletedUniversity of Turin, Italy2171999-09-012007-05-14

Conditions studied

Multiple Sclerosis (4)  ·  COVID-19 (1)  ·  Coronavirus Infections (1)  ·  Hepatitis C, Chronic (1)  ·  Macular Edema (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)  ·  Recurrence (1)  ·  Severe Acute Respiratory Syndrome (1)  ·  Uveitis (1)  ·  Uveitis, Intermediate (1)

Sponsors

Genzyme, a Sanofi Company (1)  ·  Heidelberg University (1)  ·  Population Health Research Institute (1)  ·  Sanofi (1)  ·  Tanabe Pharma Corporation (1)  ·  University Hospital, Montpellier (1)  ·  University of Turin, Italy (1)

Countries

France (3)  ·  Russia (3)  ·  Brazil (2)  ·  Canada (2)  ·  Colombia (2)  ·  Germany (2)  ·  Italy (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Chile (1)  ·  Denmark (1)  ·  Ecuador (1)

Top investigators

Alessandra Protti, M.D. (1)  ·  Andrea Spissu, M.D. (1)  ·  Angelo Ghezzi, M.D. (1)  ·  Antonio Carolei, M D (1)  ·  Arturo Reggio, Prophessor (1)  ·  Claudio Geda, M.D. (1)  ·  Domenico Caputo, M.D. (1)  ·  Elio Scarpini, M.D (1)  ·  Emilie Belley-Cote, MD PhD (1)  ·  Enrico Montanari, M.D. (1)  ·  Federico Piccoli, Prophessor (1)  ·  Francesco Teatini, M.D. (1)  ·  Franco Perla, M.D. (1)  ·  Friederike Mackensen, MD, FEBO (1)

Results publications

PMID 19278300, PMID 28497489, PMID 34658014, PMID 36228639, PMID 36228641, PMID 37489818

NIH funding

2016 (1)